S

Strand Therapeutics

Develops programmable, long-acting mRNA therapeutics

Advanced Cell Engineering Co-op

Translational Research & Bench BiologyPosted on Nov 13
InternshipBoston, MA, USA$25 - $28 /hrIn-person

About the Job

Requirements

  • Be on track to graduate with a Bachelor of Science or Master of Science in Biology, Biochemistry, Bioengineering, or a related discipline.
  • Be able to write, edit, and follow standard operating procedures, make careful observations, and maintain clear and complete laboratory records.

Responsibilities

  • Generate, expand, and maintain stable mammalian cell lines expressing proteins of interest.
  • Develop and optimize flow cytometry assays to characterize cell lines, including protein expression levels and stability over time.
  • Perform mammalian cell transfections and downstream functional assays such as in vitro cytotoxicity and enzyme-linked immunosorbent assay (ELISA) assays.
  • Execute experiments, maintain accurate laboratory records, and contribute to troubleshooting experiments with the team.
  • Work across diverse areas to support the group's research activities in a fast-paced and collaborative environment.

Desired Qualifications

  • Have 1–3 years of research experience in a biotechnology, pharmaceutical, or academic environment.
  • Have experience with mammalian cell culture, transfection, and flow cytometry.
  • Have hands-on experience with ELISAs, viral transductions, and RNA handling.
  • Have exposure to immune cell assays such as immune cell isolation, phenotyping, and co-culture.

About the Company

Strand Therapeutics

Develops programmable, long-acting mRNA therapeutics

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company size
51-200
Company stage
Series B
Total funding
$256M
Headquarters
Boston, MA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Strand Therapeutics

See more jobs